430 related articles for article (PubMed ID: 26437033)
21. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
[TBL] [Abstract][Full Text] [Related]
22. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH
J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969
[TBL] [Abstract][Full Text] [Related]
23.
Chang HY; Koh VCY; Md Nasir ND; Ng CCY; Guan P; Thike AA; Teh BT; Tan PH
J Clin Pathol; 2020 Jan; 73(1):51-56. PubMed ID: 31662438
[TBL] [Abstract][Full Text] [Related]
24. Periductal Stromal Tumor of the Breast with a
Anderson B; Marotti JD; Lefferts JA; Muller KE
Int J Surg Pathol; 2023 Dec; 31(8):1626-1631. PubMed ID: 36823780
[TBL] [Abstract][Full Text] [Related]
25. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
Otsuji K; Sasaki T; Tanabe M; Seto Y
Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
[TBL] [Abstract][Full Text] [Related]
26. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions.
Tan WJ; Cima I; Choudhury Y; Wei X; Lim JC; Thike AA; Tan MH; Tan PH
Breast Cancer Res; 2016 Mar; 18(1):31. PubMed ID: 26961242
[TBL] [Abstract][Full Text] [Related]
27. MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women.
Darooei M; Khan F; Rehan M; Zubeda S; Jeyashanker E; Annapurna S; Shah A; Maddali S; Hasan Q
J Cell Biochem; 2019 Jan; 120(1):182-191. PubMed ID: 30230586
[TBL] [Abstract][Full Text] [Related]
28. Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast.
Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2016 Mar; 35(3):1511-8. PubMed ID: 26676988
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
Wang ZC; Buraimoh A; Iglehart JD; Richardson AL
Breast Cancer Res Treat; 2006 Jun; 97(3):301-9. PubMed ID: 16791486
[TBL] [Abstract][Full Text] [Related]
30. Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.
Tan BY; Md Nasir ND; Chang HY; Ng CCY; Guan P; Nagarajan S; Rajasegaran V; Lee JY; Lim JQ; Thike AA; Teh BT; Tan PH
Mod Pathol; 2020 Sep; 33(9):1732-1745. PubMed ID: 32322022
[TBL] [Abstract][Full Text] [Related]
31. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
[TBL] [Abstract][Full Text] [Related]
32. A Diagnostic Approach to Fibroepithelial Breast Lesions.
Tan BY; Tan PH
Surg Pathol Clin; 2018 Mar; 11(1):17-42. PubMed ID: 29413655
[TBL] [Abstract][Full Text] [Related]
33. Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast.
Kang Y; Kim JH; Lee TH; Kim TS; Jung WH; Chung HC; Park BW; Sheen SS; Han JH
Hum Pathol; 2009 Jan; 40(1):98-107. PubMed ID: 18789487
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast.
Huang KT; Dobrovic A; Yan M; Karim RZ; Lee CS; Lakhani SR; Fox SB
Breast Cancer Res Treat; 2010 Nov; 124(2):555-65. PubMed ID: 20563638
[TBL] [Abstract][Full Text] [Related]
35. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
Gatalica Z; Vranic S; Ghazalpour A; Xiu J; Ocal IT; McGill J; Bender RP; Discianno E; Schlum A; Sanati S; Palazzo J; Reddy S; Pockaj B
Oncotarget; 2016 Jan; 7(2):1707-16. PubMed ID: 26625196
[TBL] [Abstract][Full Text] [Related]
36. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast.
Feakins RM; Wells CA; Young KA; Sheaff MT
Hum Pathol; 2000 Oct; 31(10):1214-22. PubMed ID: 11070114
[TBL] [Abstract][Full Text] [Related]
37. Phyllodes tumors and fibroadenoma common beginning and different ending.
Oprić S; Oprić D; Gugić D; Granić M
Coll Antropol; 2012 Mar; 36(1):235-41. PubMed ID: 22816226
[TBL] [Abstract][Full Text] [Related]
38. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.
Lim WK; Ong CK; Tan J; Thike AA; Ng CC; Rajasegaran V; Myint SS; Nagarajan S; Nasir ND; McPherson JR; Cutcutache I; Poore G; Tay ST; Ooi WS; Tan VK; Hartman M; Ong KW; Tan BK; Rozen SG; Tan PH; Tan P; Teh BT
Nat Genet; 2014 Aug; 46(8):877-80. PubMed ID: 25038752
[TBL] [Abstract][Full Text] [Related]
39. Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors.
Lawton TJ; Acs G; Argani P; Farshid G; Gilcrease M; Goldstein N; Koerner F; Rowe JJ; Sanders M; Shah SS; Reynolds C
Int J Surg Pathol; 2014 Dec; 22(8):695-8. PubMed ID: 25161205
[TBL] [Abstract][Full Text] [Related]
40. Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon.
Djordjevic B; Hanna WM
Mod Pathol; 2008 Oct; 21(10):1238-45. PubMed ID: 18500266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
